Literature DB >> 27814612

miRNAs as drivers of TMPRSS2-ERG negative prostate tumors in African American men.

Clayton Yates1, Mark D Long2, Moray J Campbell3, Lara Sucheston-Campbell4.   

Abstract

African Americans (AAs) who have PCa typically have more aggressive disease and make up a disproportionate number of the disease deaths, relative to European Americans (EAs). TMPRSS2 translocations, a common event in EA patients, are exploited in diagnostic and prognostic settings, whereas they are diminished in frequency in AA men. Thus, these patients with TMPRSS2 fusion-negative disease represent an under-investigated patient group. We propose that epigenetic events are a significant and alternative driver of aggressive disease in fusion-negative PCa. To reveal epigenetically governed microRNAs (miRNAs) that are enriched in fusion-negative disease and associated with aggressive in AA PCa, we leveraged both our experimental evidence and publically available data. These analyses identified 18 miRNAs that are differentially altered in fusion-negative disease, associated with DNA CpG methylation, and implicated in aggressive and AA PCas. Understanding the relationships between miRNA expression, upstream epigenetic regulation by DNA methylation, and downstream regulation of mRNA targets in fusion negative disease is imperative to understanding the biological basis of the racial health disparity in PCa.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 27814612      PMCID: PMC5858730          DOI: 10.2741/4482

Source DB:  PubMed          Journal:  Front Biosci (Landmark Ed)        ISSN: 2768-6698


  134 in total

Review 1.  Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes.

Authors:  Michael S Cookson; Gunnar Aus; Arthur L Burnett; Edith D Canby-Hagino; Anthony V D'Amico; Roger R Dmochowski; David T Eton; Jeffrey D Forman; S Larry Goldenberg; Javier Hernandez; Celestia S Higano; Stephen R Kraus; Judd W Moul; Catherine Tangen; J Brantley Thrasher; Ian Thompson
Journal:  J Urol       Date:  2007-02       Impact factor: 7.450

2.  TMPRSS2-ERG gene fusion prevalence and class are significantly different in prostate cancer of Caucasian, African-American and Japanese patients.

Authors:  Cristina Magi-Galluzzi; Toyonori Tsusuki; Paul Elson; Kelly Simmerman; Chris LaFargue; Raquel Esgueva; Eric Klein; Mark A Rubin; Ming Zhou
Journal:  Prostate       Date:  2010-09-28       Impact factor: 4.104

3.  Inactivation of AR/TMPRSS2-ERG/Wnt signaling networks attenuates the aggressive behavior of prostate cancer cells.

Authors:  Yiwei Li; Dejuan Kong; Zhiwei Wang; Aamir Ahmad; Bin Bao; Subhash Padhye; Fazlul H Sarkar
Journal:  Cancer Prev Res (Phila)       Date:  2011-06-16

4.  Commentary on "The evolutionary history of lethal metastatic prostate cancer." Gundem G, Van Loo P, Kremeyer B, Alexandrov LB, Tubio JM, Papaemmanuil E, Brewer DS, Kallio HM, Högnäs G, Annala M, Kivinummi K, Goody V, Latimer C, O'Meara S, Dawson KJ, Isaacs W, Emmert-Buck MR, Nykter M, Foster C, Kote-Jarai Z, Easton D, Whitaker HC, ICGC Prostate UK Group, Neal DE, Cooper CS, Eeles RA, Visakorpi T, Campbell PJ, McDermott U, Wedge DC, Bova GS, University of Washington-Urology, Seattle, WA. Nature 2015; 520(7547):353-7.

Authors:  Daniel Lin
Journal:  Urol Oncol       Date:  2016-11       Impact factor: 3.498

5.  miR-376b-5p regulates angiogenesis in cerebral ischemia.

Authors:  Ling-Juan Li; Qing Huang; Ning Zhang; Gui-Bin Wang; Yun-Hai Liu
Journal:  Mol Med Rep       Date:  2014-04-24       Impact factor: 2.952

6.  Serum miRNA-21: elevated levels in patients with metastatic hormone-refractory prostate cancer and potential predictive factor for the efficacy of docetaxel-based chemotherapy.

Authors:  Hai-Liang Zhang; Li-Feng Yang; Yao Zhu; Xu-Dong Yao; Shi-Lin Zhang; Bo Dai; Yi-Ping Zhu; Yi-Jun Shen; Guo-Hai Shi; Ding-Wei Ye
Journal:  Prostate       Date:  2010-09-14       Impact factor: 4.104

7.  Prostate cancer biomarker profiles in urinary sediments and exosomes.

Authors:  Siebren Dijkstra; Ingrid L Birker; Frank P Smit; Gisele H J M Leyten; Theo M de Reijke; Inge M van Oort; Peter F A Mulders; Sander A Jannink; Jack A Schalken
Journal:  J Urol       Date:  2013-11-07       Impact factor: 7.450

8.  TMPRSS2:ERG fusion identifies a subgroup of prostate cancers with a favorable prognosis.

Authors:  Outi R Saramäki; Anna E Harjula; Paula M Martikainen; Robert L Vessella; Teuvo L J Tammela; Tapio Visakorpi
Journal:  Clin Cancer Res       Date:  2008-06-01       Impact factor: 12.531

9.  TMPRSS2- driven ERG expression in vivo increases self-renewal and maintains expression in a castration resistant subpopulation.

Authors:  Orla M Casey; Lei Fang; Paul G Hynes; Wassim G Abou-Kheir; Philip L Martin; Heather S Tillman; Gyorgy Petrovics; Hibah O Awwad; Yvona Ward; Ross Lake; Luhua Zhang; Kathleen Kelly
Journal:  PLoS One       Date:  2012-07-30       Impact factor: 3.240

10.  African American men with low-grade prostate cancer have increased disease recurrence after prostatectomy compared with Caucasian men.

Authors:  Kosj Yamoah; Curtiland Deville; Neha Vapiwala; Elaine Spangler; Charnita M Zeigler-Johnson; Bruce Malkowicz; David I Lee; Michael Kattan; Adam P Dicker; Timothy R Rebbeck
Journal:  Urol Oncol       Date:  2014-10-07       Impact factor: 3.498

View more
  7 in total

Review 1.  Epigenetic basis of cancer health disparities: Looking beyond genetic differences.

Authors:  Aamir Ahmad; Shafquat Azim; Haseeb Zubair; Mohammad Aslam Khan; Seema Singh; James E Carter; Rodney P Rocconi; Ajay P Singh
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2017-01-17       Impact factor: 10.680

2.  The extrema of circulating miR-17 are identified as biomarkers for aggressive prostate cancer.

Authors:  Greg Dyson; Batoul Farran; Susan Bolton; Douglas B Craig; Alan Dombkowski; Jennifer L Beebe-Dimmer; Isaac J Powell; Izabela Podgorski; Lance K Heilbrun; Cathryn H Bock
Journal:  Am J Cancer Res       Date:  2018-10-01       Impact factor: 6.166

3.  A study of circulating microRNAs identifies a new potential biomarker panel to distinguish aggressive prostate cancer.

Authors:  Batoul Farran; Gregory Dyson; Douglas Craig; Alan Dombkowski; Jennifer L Beebe-Dimmer; Isaac J Powell; Izabela Podgorski; Lance Heilbrun; Susan Bolton; Cathryn H Bock
Journal:  Carcinogenesis       Date:  2018-04-05       Impact factor: 4.944

4.  Diagnostic and prognostic value of microRNA-628 for cancers.

Authors:  Jing-Hua Li; Shan-Shan Sun; Chang-Jin Fu; An-Qi Zhang; Chen Wang; Rong Xu; Shu-Yang Xie; Ping-Yu Wang
Journal:  J Cancer       Date:  2018-04-12       Impact factor: 4.207

5.  miRNA-106a and prostate cancer radioresistance: a novel role for LITAF in ATM regulation.

Authors:  Christianne Hoey; Jessica Ray; Jouhyun Jeon; Xiaoyong Huang; Samira Taeb; Jarkko Ylanko; David W Andrews; Paul C Boutros; Stanley K Liu
Journal:  Mol Oncol       Date:  2018-06-14       Impact factor: 6.603

6.  Altered expression of miRNAs and mRNAs reveals the potential regulatory role of miRNAs in the developmental process of early weaned goats.

Authors:  Rongrong Liao; Yuhua Lv; Lihui Zhu; Yuexia Lin
Journal:  PLoS One       Date:  2019-08-08       Impact factor: 3.240

7.  Assessing COVID-19 susceptibility through analysis of the genetic and epigenetic diversity of ACE2-mediated SARS-CoV-2 entry.

Authors:  Georgia Ragia; Vangelis G Manolopoulos
Journal:  Pharmacogenomics       Date:  2020-11-27       Impact factor: 2.533

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.